NPS Pharmaceuticals suffered a knock-back yesterday, when the US Court of Appeals for the Federal Circuit affirmed a decision which found that claims covering a patent owned by NPS were unpatentable.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
15 May 2018 The US Court of Appeals for the Federal Circuit has affirmed a Patent Trial and Appeal Board decision to invalidate a patent after a coalition formed by Kyle Bass requested a review.
15 May 2018 The US Court of Appeals for the Federal Circuit has affirmed a Patent Trial and Appeal Board decision to invalidate a patent after a coalition formed by Kyle Bass requested a review.
15 May 2018 The US Court of Appeals for the Federal Circuit has affirmed a Patent Trial and Appeal Board decision to invalidate a patent after a coalition formed by Kyle Bass requested a review.